Merck & Co., Inc. (MRK)
NYSE: MRK · IEX Real-Time Price · USD
125.26
-0.59 (-0.47%)
Jul 26, 2024, 4:00 PM EDT - Market closed
Merck & Co. Revenue
Merck & Co. had revenue of $15.78B in the quarter ending March 31, 2024, with 8.89% growth. This brings the company's revenue in the last twelve months to $61.40B, up 6.11% year-over-year. In the year 2023, Merck & Co. had annual revenue of $60.12B with 1.40% growth.
Revenue (ttm)
$61.40B
Revenue Growth
+6.11%
P/S Ratio
5.21
Revenue / Employee
$852,806
Employees
72,000
Market Cap
317.26B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 60.12B | 832.00M | 1.40% |
Dec 31, 2022 | 59.28B | 10.58B | 21.72% |
Dec 31, 2021 | 48.70B | 7.19B | 17.31% |
Dec 31, 2020 | 41.52B | 2.40B | 6.13% |
Dec 31, 2019 | 39.12B | -3.17B | -7.50% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 379.49B |
Johnson & Johnson | 81.80B |
AbbVie | 54.40B |
Novartis AG | 48.86B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.49B |
Abbott Laboratories | 40.33B |
Eli Lilly | 35.93B |
MRK News
- 7 hours ago - Germany's Merck raises 2024 sales forecast - Reuters
- 12 hours ago - Is An Earnings Beat In The Cards For Merck Stock? - Forbes
- 13 hours ago - Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma - Business Wire
- 3 days ago - Merck Announces Fourth-Quarter 2024 Dividend - Business Wire
- 3 days ago - Merck's RSV drug meets main goals of mid-to-late stage trial - Reuters
- 3 days ago - Merck Announces Topline Results from Phase 2b/3 Trial of Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus Preventative Monoclonal Antibody for Infants - Business Wire
- 10 days ago - Merck to Share New Research and Host Community-Focused Symposia at AIDS 2024 - Business Wire
- 10 days ago - Jeito Capital consolidates its support in CatalYm with a renewed participation in a $150 million financing - GlobeNewsWire